AA
CVS icon

Altrafin AG’s CVS Health CVS Stock Holding History

Altrafin AG’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,040
Closed -$900K – 46
2024
Q4 		$900K Hold
20,040
– – 0.31% 38
2024
Q3 		$1.26M Hold
20,040
– – 0.45% 36
2024
Q2 		$1.18M Buy
20,040
+5,500
+38% +$344K 0.44% 40
2024
Q1 		$1.16M Sell
14,540
-81,470
-85% -$6.22M 0.42% 44
2023
Q4 		$7.58M Sell
96,010
-1,640
-2% -$117K 2.92% 11
2023
Q3 		$6.82M Buy
97,650
+35,525
+57% +$2.52M 2.97% 7
2023
Q2 		$4.29M Hold
62,125
– – 1.93% 21
2023
Q1 		$4.62M Buy
62,125
+176
+0.3% +$14.8K 2.27% 15
2022
Q4 		$5.77M Sell
61,949
-2,680
-4% -$259K 3.38% 6
2022
Q3 		$6.16M Sell
64,629
-13,176
-17% -$1.3M 3.69% 4
2022
Q2 		$7.21M Sell
77,805
-8,710
-10% -$850K 3.89% 4
2022
Q1 		$8.76M Sell
86,515
-6,637
-7% -$697K 3.44% 4
2021
Q4 		$9.61M Buy
+93,152
New +$8.61M 3.47% 4

Other funds holding CVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Altrafin AG's CVS Position: Q1 2025 in Review

Altrafin AG sold out of CVS Health (CVS) in Q1 2025, closing a stake of 20,040 shares — an estimated $900K sold.

Altrafin AG first reported a position in CVS in Q4 2021 and held it in 13 quarters. The position peaked at $9.61M in Q4 2021. 1,752 funds tracked by Wall St. Rank hold CVS as of Q1 2025.

  • Altrafin AG reported no remaining CVS Health position as of Q1 2025 after selling out during the quarter.
  • Altrafin AG sold 20,040 CVS Health shares in Q1 2025, an estimated $900K.
  • Altrafin AG first reported a position in CVS Health in Q4 2021 and held it in 13 quarters.
  • Altrafin AG's CVS Health position peaked at $9.61M in Q4 2021.
  • 1,752 funds tracked by Wall St. Rank held CVS Health as of Q1 2025.

Based on Altrafin AG's 13F filing for Q1 2025, filed 17 Feb 2026.